Introduction
============

Biliary tract cancer (BTC) is a heterogeneous subgroup of tumors, including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer, and ampulla of Vater cancer. BTC has a very poor prognosis. Therapeutic options for patients with BTC include surgery, photodynamic therapy, radiation therapy, liver transplantation, chemoradiation therapy, and chemotherapy. Complete resection could improve long-term survival, but the diagnosis of BTC is often challenging and as such, many cases are inoperable by the time of diagnosis. For patients with inoperable disease, gemcitabine in combination with cisplatin has been administered as the standard chemotherapy regimen. Prior to the establishment of a standard regimen, many chemotherapeutic agents were studied for their efficacy against advanced BTC, but the majority of studies have had limited value in establishing a standard regimen because of a small sample size or non-randomized design; therefore, there have been no promising results in randomized phase III studies.

To develop a standard chemotherapy regimen, a phase III clinical study of a chemotherapy drug with proven efficacy and safety must be conducted, comparing the outcomes of the chemotherapy drug versus those of best supportive care (BSC). In pancreatic cancer, 5-fluorouracil (5-FU)‒based chemotherapy was shown to be superior over BSC in the late 1970s, and thereafter, the survival rates have improved stepwise with 5-FU and more effective drugs \[[@b1-crt-2017-044]-[@b3-crt-2017-044]\]. Recently, many studies for second-line chemotherapy treatment of advanced BTC have been published \[[@b4-crt-2017-044],[@b5-crt-2017-044]\]. Most patients with advanced BTC had outcomes that were comparable with those reported in previous studies; however, frontline chemotherapy provides a survival benefit for many patients, even if it is not effective for everyone with advanced BTC. In fact, depending on the clinical situation, advanced BTC has considerable variation with respect to chemotherapy response and survival time. Therefore, a survival comparison between advanced BTC patients with the same conditions receiving chemotherapy or BSC should aid clinicians in identifying the appropriate candidates for palliative chemotherapy.

In our previous study \[[@b6-crt-2017-044]\], the natural history of inoperable BTC was only 7.1 months, but patients with low levels of tumor markers or locally advanced BTC had modest survival times (10.6 months and 13.8 months, respectively) without any treatment. This survival time was comparable to historical data from patients with advanced BTC who received chemotherapy. As an extension of our earlier study, we conducted a comparative analysis between chemotherapy and BSC in patients with advanced BTC, applying propensity score matching (PSM) to evaluate variables that were disproportionate between the groups.

Materials and Methods
=====================

1. Patient populations
----------------------

### 1) BSC group

The data for the BSC group were collected at six cancer centers in Korea. We selected 206 patients who met the following criteria for inclusion in the study: (1) histologic diagnosis of locally advanced or metastatic BTC, or (2) Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (eligible to receive chemotherapy). Exclusion criteria were patients who had (1) undergone curative surgery, chemotherapy, and radiation therapy for primary cancer; (2) initially resectable disease; or (3) an ECOG performance status of 3-4. The data on this cohort were reported elsewhere in detail \[[@b6-crt-2017-044]\].

### 2) Chemotherapy group

Data for the chemotherapy group were collected at four cancer centers in Korea. We selected 398 patients who met the following criteria for inclusion in the study: (1) a histologic diagnosis of locally advanced or metastatic BTC, (2) administration of frontline chemotherapy, and (3) an ECOG performance status of 0-2. Patients who had (1) undergone curative surgery and radiation therapy for primary cancer, (2) initially resectable disease, or (3) an ECOG performance status of 3-4 were excluded from the study.

2. Variables included in the study
----------------------------------

Baseline characteristics included age, sex, disease status (locally advanced or metastatic disease), ECOG performance status, frontline chemotherapy regimen, white blood cell (WBC) count, neutrophil/lymphocyte/monocyte counts, red cell distribution width, mean cell volume, hemoglobin level, platelet count, erythrocyte sedimentation rate, C-reactive protein, albumin, total bilirubin, alkaline phosphatase, aspartate aminotransferase (AST), alanine transaminase (ALT), carcinoembryonic antigen (CEA), and cancer antigen 19-9 (CA 19-9) levels, and whether or not biliary drainage was performed. The cut-off level of categorical variables was defined as follows: ECOG 0-1 and 2; CA 19-9 ≤ 100 IU/mL and \> 100 IU/mL; CEA ≤ 3.4 ng/mL and \> 3.4 ng/mL; WBC \< 3,500 cells/mm^3^, 3,500 cells/mm^3^ ≤ WBC \< 10,000 cells/mm^3^, and WBC ≥ 10,000 cells/mm^3^.

The continuous variables were reported as the mean±standard deviation (SD) and compared using Student's t test. The categorical variables were described as percentages and were compared using chi-square tests.

3. PSM and statistical analysis
-------------------------------

Our study was not a randomized, multicenter study, so the decision of whether to administer frontline chemotherapy in our study cohort was based on clinician discretion and patient preference. To overcome this selection bias, we performed PSM; the propensity score was calculated from a logistic regression model, and for PSM, seven baseline clinical and laboratory metrics including age (years), performance status (ECOG), CEA level, WBC level, albumin level, total bilirubin level, and AST level, were selected. With the propensity score estimated, 164 pairs of patients were matched using a 1:1 nearest neighbor matching algorithm. All statistical analyses were performed using SPSS for Windows ver. 21.0 (IBM Corp., Armonk, NY) and StataCorp. 2015, Stata Statistical Software: Release 14 (College Station, TX). Survival information was collected by the National Health Insurance Service, median survival was estimated using the Kaplan-Meier method, and comparisons between the groups were performed using the log-rank test. A p-value of less than 0.05 was considered statistically significant.

4. Ethical statement
--------------------

This study was conducted in Korea, and Institutional Review Board approval was obtained. The study was a retrospective database review without any intervention or use of human specimens, and the requirement for informed consent was waived.

Results
=======

1. Patient characteristics
--------------------------

A total of 604 patients with advanced BTC met our inclusion criteria; 206 were treated with only BSC without any curative treatments (chemotherapy, surgery, and radiation therapy) until their death, and 398 were treated with frontline chemotherapy.

In the pre-PSM cohort, the age of the patients was significantly older in the BSC group than in the chemotherapy group (mean±SD, 60.7±10 years vs. 69.9±10.6 years; p \< 0.001). The BSC group also had poor performance statuses and high rates of abnormal laboratory findings (albumin, total bilirubin, AST, and ALT levels) compared with the chemotherapy group. No significant differences were observed in other variables between both groups.

A total of 328 patients were matched and baseline characteristics were balanced and matched, with the exception of some laboratory variables, between the two groups. The baseline characteristics of the enrolled patients before and after PSM are listed in [Table 1](#t1-crt-2017-044){ref-type="table"}.

2. Comparison of survival outcomes
----------------------------------

In the pre-PSM cohort, the median overall survival (OS) was 15.2 months versus 7.0 months for all cohorts in the chemotherapy group versus the BSC group. In the subgroup analysis, OS was significantly longer in the chemotherapy arm of most subgroups, except for the subgroup with an ECOG score of 2 (8.4 months for the chemotherapy group vs. 6.1 months for the BSC group, p=0.603) (detailed results are shown in [Table 2](#t2-crt-2017-044){ref-type="table"}).

In the PSM cohort, the median OS was 12.0 months in patients given frontline chemotherapy versus 7.5 months in patients receiving BSC for all cohorts ([Fig. 1](#f1-crt-2017-044){ref-type="fig"}). In the subgroups of patients with locally advanced disease, ECOG 2, female, CA 19-9 ≤ 100 IU/mL, or CEA ≤ 3.4 ng/mL there were no significant differences in OS between the chemotherapy group and the BSC group (16.7 months vs. 13.4 months \[p=0.490\], 8.4 months vs. 6.3 months \[p=0.568\], 11.3 months vs. 6.0 months \[p=0.223\], 12.7 months vs. 10.6 months \[p=0.330\], and 17.1 months vs. 10.6 months \[p=0.052\], respectively). In the rest of the subgroups, frontline chemotherapy demonstrated a significant survival benefit ([Table 2](#t2-crt-2017-044){ref-type="table"}, [Fig. 2](#f2-crt-2017-044){ref-type="fig"}). Survival analysis by the disease location revealed that there were no significant survival differences in ampulla of Vater cancer (chemotherapy group of 12.7 months vs. BSC group of 12.9 months, p=0.481). But frontline chemotherapy is associated with longer survival in cholangiocarcinoma (chemotherapy group of 12.8 months vs. BSC group of 7.1 months, p=0.003) and gallbladder cancer (chemotherapy group of 11.1 months vs. BSC group of 4.2 months, p=0.022).

Further analyses were performed in the intersectional cohorts that consisted of subgroups with minor differences between the chemotherapy group and the BSC group. In the intersectional cohort with subgroups of locally advanced disease and CA 19-9 ≤ 100 IU/mL/locally advanced disease and CEA ≤ 3.4 ng/mL/CA 19-9 ≤ 100 IU/mL and CEA ≤ 3.4 ng/mL, there were consistently no significant differences in survival between the chemotherapy group and the BSC group (23.6 months vs. 23.8 months \[p=0.509\], 27.1 months vs. 26.9 months \[p=0.575\], and 39.1 months vs. 18.8 months \[p=0.325\], respectively) ([Fig. 3](#f3-crt-2017-044){ref-type="fig"}).

Discussion
==========

Although the standard treatment of inoperable BTC is combination chemotherapy with cisplatin plus gemcitabine, the efficacy of chemotherapy in advanced BTC is poor. The current use of chemotherapy in advanced BTC was extrapolated from evidence in pancreatic cancer \[[@b7-crt-2017-044]\]. Herein, we have shown clear evidence that chemotherapy could increase the survival rates of advanced BTC patients. Particularly, chemotherapy must be considered in cases of metastatic disease or good performance status (ECOG 0-1) or high level of tumor marker.

This study also suggests that not all patients with advanced BTC are suitable candidates for chemotherapy. There was no statistical difference between the BSC and frontline chemotherapy cohorts of advanced BTC patients with locally advanced disease and/or low levels of tumor markers. In particular, this tendency was noticeable in patients with locally advanced disease and low levels of tumor markers (CA 19-9 ≤ 100 IU/mL/CEA ≤ 3.4 ng/mL). This means that in these subgroups, immediate chemotherapy may not improve survival time. Levels of tumor markers and patient disease status are therefore important factors to consider when deciding whether or not to administer palliative chemotherapy. An additional comparative cohort study will aid in determining the optimal timing of chemotherapy; tailored treatment plans will be required for advanced BTC.

In BTC, little is known about the natural course of the disease without any cancer treatment. The majority of studies on the natural progression of BTC used a retrospective design, and a large number of the enrolled participants who were treated with only BSC already had untreatable disease with a poor performance status \[[@b8-crt-2017-044],[@b9-crt-2017-044]\]. As such, the determined survival time of advanced BTC without any treatment is highly inaccurate and generally short. In our previous analysis of national insurance data \[[@b6-crt-2017-044]\], we showed that the survival time of patients with untreated advanced BTC with locally advanced disease or low levels of tumor markers (CA 19-9 ≤ 100 IU/mL or CEA ≤ 3.4 ng/mL) was comparable to that of advanced BTC patients who were treated with cisplatin plus gemcitabine. Using the available data for the natural course of advanced BTC, a PSM analysis was used for the comparison of frontline chemotherapy and BSC. Since the first use of PSM \[[@b10-crt-2017-044]\], many comparative studies have been conducted using PSM when randomized trials were not possible. In the current circumstances of advanced BTC, in which cisplatin plus gemcitabine is already considered the standard therapy, a randomized comparative study is not feasible for ethical reasons. Accordingly, our PSM analysis is the proper method to compare frontline chemotherapy and BSC in advanced BTC patients with a good performance status.

Appropriate practical guidance regarding the timing of chemotherapy initiation is lacking. Several available studies are limited to the adjuvant setting, and delayed timeto-chemotherapy may have a negative prognostic impact in breast cancer and colorectal cancer \[[@b11-crt-2017-044]-[@b14-crt-2017-044]\]. This trend is predominantly observed in the subgroup of patients with a poor prognosis when the remainder of the subgroup has a fair prognosis \[[@b15-crt-2017-044]\]. This is consistent with our results, which indicate that the prompt initiation of chemotherapy in a subgroup of advanced BTC patients with a good prognosis does not prolong survival. In the palliative setting, the generally accepted practice is that the earlier the initiation of chemotherapy the better. However, this is not always the case. A meta-analysis of data on metastatic colorectal cancer found no difference in OS, time-to-progression, or quality of life with immediate versus delayed chemotherapy \[[@b16-crt-2017-044]\]. There is no clear recommendation regarding the timing of chemotherapy initiation in BTC, and considering the various clinical courses of BTC, more research is necessary to better determine the optimal timing of chemotherapy in advanced BTC.

The current study has several limitations. Retrospective design is the first weak point. To reduce bias for retrospective design, we applied PSM analysis. As a stratification parameter, we selected variables by a multivariate analysis including age, extent of disease, ECOG status albumin level, total bilirubin level and AST level. Small sample size is the second weak point. The disease location is important prognostic factor but we could not include because of small sample size. Survival benefit was not observed between chemotherapy group and BSC group in specific subgroups but the result in the subgroups of CEA ≤ 3.4 or locally advanced disease just could not satisfy statistical significance, the trend of survival was superior in chemotherapy group. If we analyzed a larger sample size, survival benefit might be favorable to the chemotherapy group. However, as we investigated credible insurance OS data and intersectional analysis, we focused on the possibility that urgent chemotherapy is not needed in some cases of BTC patient.

Actually in our previous study \[[@b6-crt-2017-044]\], median survival time by the disease location were ampullary cancer (11.2 months) followed by extrahepatic cholangiocarcinoma (9.7 months), intrahepatic cholangiocarcinoma (4.7 months), and gallbladder cancer (4.4 months). Recently, interest for quality of life (QoL) is increasing and it is as important as survival result in study for cancer. Evaluation of QoL was not performed as well in our study for the retrospective analysis.

In conclusion, our results suggest that chemotherapy in advanced BTC is mostly beneficial for survival. Especially in subgroups with metastatic disease, high tumor marker or good performance status (ECOG 0-1) this trend is evident. The other way, immediate chemotherapy may not be helpful to someone who had low tumor marker, poor performance status or localized disease. The identification of prognostic subgroups classified by their clinical and laboratory characteristics is important for optimizing the timing of the initiation of palliative chemotherapy. In addition, further genomic research to validate our results is needed, as is an additional prospective study focusing on the timeliness of chemotherapy initiation in advanced BTC.
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###### 

Baseline characteristics of the patients

  Characteristic              Before propensity score matched   After propensity score matched                                        
  --------------------------- --------------------------------- -------------------------------- ---------- ------------ ------------ -------
  **Sex**                                                                                                                             
   Male                       226 (56.8)                        115 (55.8)                       0.863      93 (56.7)    91 (55.5)    0.911
   Female                     172 (43.2)                        91 (44.2)                                   71 (43.3)    73 (44.5)    
  **Age**                     60.7±10.0                         69.9±10.6                        \< 0.001   67.4±6.7     67.9±10.1    0.592
  **Extent of disease**                                                                                                               
   locally advanced           110 (27.7)                        42 (22.7)                        0.224      29 (17.7)    36 (22.0)    0.406
   Metastatic                 287 (72.3)                        143 (77.3)                                  135 (82.3)   128 (78.0)   
  **ECOG**                                                                                                                            
   0 or 1                     346 (86.9)                        125 (60.7)                       \< 0.001   116 (70.7)   109 (66.5)   0.475
   2                          52 (13.1)                         81 (39.3)                                   48 (29.3)    55 (33.5)    
  **CA 19-9 (IU/mL)**                                                                                                                 
   ≤ 100                      175 (48.9)                        84 (43.5)                        0.245      63 (42.3)    67 (43.8)    0.817
   \> 100                     183 (51.1)                        109 (56.5)                                  86 (57.7)    86 (56.2)    
  **CEA (ng/mL)**                                                                                                                     
   ≤ 3.4                      172 (50.6)                        73 (41.5)                        0.051      56 (40.3)    58 (40.6)    1.000
   \> 3.4                     168 (49.4)                        103 (58.5)                                  83 (59.7)    85 (59.4)    
  **WBC (cell/mm^3^)**                                                                                                                
   \< 3,500                   18 (4.5)                          4 (1.9)                          0.050      9 (5.5)      4 (2.4)      0.311
   ≥ 3,500 and \< 10,000      308 (77.6)                        151 (73.3)                                  120 (73.2)   119 (72.6)   
   ≥ 10,000                   71 (17.9)                         51 (24.8)                                   35 (21.3)    41 (25.0)    
  **Platelet (×103/mm^3^)**                                                                                                           
   \< 130                     43 (11.5)                         17 (8.3)                         0.460      23 (15.3)    14 (8.5)     0.180
   ≥ 130 and \< 400           303 (81)                          174 (84.5)                                  115 (76.7)   136 (82.9)   
   ≥ 400                      28 (7.5)                          15 (7.3)                                    12 (8.0)     14 (8.5)     
  **Albumin (mg/dL)**                                                                                                                 
   ≤ 3.5                      112 (28.2)                        101 (49)                         \< 0.001   78 (47.6)    79 (48.2)    1.000
   3.5-5.2                    285 (71.8)                        105 (51)                                    86 (52.4)    85 (51.8)    
  **T.bilirubin (mg/dL)**                                                                                                             
   ≤ 1.2                      315 (79.3)                        104 (50.5)                       \< 0.001   100 (61.0)   88 (53.7)    0.219
   \> 1.2                     82 (20.7)                         102 (49.5)                                  64 (39.0)    76 (46.3)    
  **ALP (IU/L)**                                                                                                                      
   ≤ 80                       70 (17.6)                         31 (15)                          0.490      22 (13.4)    25 (15.2)    0.753
   \> 80                      327 (82.4)                        175 (85)                                    142 (86.6)   139 (84.8)   
  **AST (IU/L)**                                                                                                                      
   ≤ 40                       275 (69.3)                        100 (48.5)                       \< 0.001   91 (55.5)    86 (52.4)    0.658
   \> 40                      122 (30.7)                        106 (51.5)                                  73 (44.5)    78 (47.6)    
  **ALT (IU/L)**                                                                                                                      
   ≤ 40                       291 (73.3)                        111 (53.9)                       \< 0.001   105 (64.0)   92 (56.1)    0.176
   \> 40                      106 (26.7)                        95 (46.1)                                   59 (36.0)    72 (43.9)    
  **Origin site**                                                                                                                     
   Bile duct                                                                                                119 (72.6)   122 (74.4)   0.615
   Ampulla of Vater                                                                                         12 (7.3)     15 (9.1)     
   Gallbladder                                                                                              33 (20.1)    27 (16.5)    

Values are presented as number (%) or mean±standard deviation. ECOG, Eastern Cooperative Oncology Group; CA 19-9, cancer antigen 19-9; CEA, carcinoembryonic antigen; WBC, white blood cell; T.bilirubin, total bilirubin; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine transaminase.

###### 

Overall survival of the subgroups

  Group                      Before PSM (n=604)   After PSM (n=328)          
  -------------------------- -------------------- ------------------- ------ ----------
  **All cohort**                                                             
   Chemotherapy              15.2                 \< 0.001            12.0   0.001
   BSC                       7.0                                      7.5    
   Total                     12.1                                     9.6    
  **Locally advanced**                                                       
   Chemotherapy              28.0                 0.010               16.7   0.490
   BSC                       13.4                                     13.4   
   Total                     23.4                                     14.8   
  **Metastatic**                                                             
   Chemotherapy              12.7                 \< 0.001            11.1   \< 0.001
   BSC                       6.2                                      6.3    
   Total                     9.6                                      8.3    
  **ECOG 0-1**                                                               
   Chemotherapy              17.0                 \< 0.001            13.7   0.001
   BSC                       8.8                                      8.4    
   Total                     14.2                                     11.3   
  **ECOG 2**                                                                 
   Chemotherapy              8.4                  0.603               8.4    0.568
   BSC                       6.1                                      6.3    
   Total                     6.6                                      6.6    
  **CA 19-9 ≤ 100 IU/mL**                                                    
   Chemotherapy              19.8                 0.001               12.7   0.330
   BSC                       10.6                                     10.6   
   Total                     16.2                                     12.3   
  **CA 19-9 \> 100 IU/mL**                                                   
   Chemotherapy              11.8                 \< 0.001            10.9   0.001
   BSC                       6.0                                      6.0    
   Total                     9.1                                      8.2    
  **CEA ≤ 3.4 ng/mL**                                                        
   Chemotherapy              20.9                 0.007               17.1   0.052
   BSC                       11.5                                     10.6   
   Total                     17.8                                     12.3   
  **CEA \> 3.4 ng/mL**                                                       
   Chemotherapy              10.2                 \< 0.001            9.6    0.037
   BSC                       4.9                                      5.1    
   Total                     8.2                                      6.7    
  **Male**                                                                   
   Chemotherapy              14.7                 \< 0.001            12.8   0.001
   BSC                       8.2                                      8.3    
   Total                     12.0                                     10.3   
  **Female**                                                                 
   Chemotherapy              16.5                 \< 0.001            11.3   0.223
   BSC                       6.0                                      6.0    
   Total                     12.4                                     8.6    

PSM, propensity score matched; MS, median survival; BSC, best supportive care; ECOG, Eastern Cooperative Oncology Group; CA 19-9, cancer antigen 19-9; CEA, carcinoembryonic antigen.
